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OBJECTIVEdIt is unclear whether coronary artery calcium (CAC) is effective for risk strat-
ifying patients with diabetes in whom treatment decisions are uncertain.
RESEARCH DESIGN ANDMETHODSdOf 44,052 asymptomatic individuals referred
for CAC testing, we studied 2,384 individuals with diabetes. Subjects were followed for amean of
5.6 6 2.6 years for the end point of all-cause mortality.
RESULTSdThere were 162 deaths (6.8%) in the population. CAC was a strong predictor of
mortality across age-groups (age ,50, 50–59, $60), sex, and risk factor burden (0 vs. $1
additional risk factor). In individuals without a clear indication for aspirin per current guidelines,
CAC stratified risk, identifying patients above and below the 10% risk threshold of presumed
aspirin benefit.
CONCLUSIONSdCAC can help risk stratify individuals with diabetes and may aid in selec-
tion of patients who may benefit from therapies such as low-dose aspirin for primary prevention.
Diabetes Care 35:624–626, 2012
A lthough diabetes has been con-sidered a coronary heart disease(CHD) risk equivalent (1), not all
individuals with diabetes carry equivalent
risk. Coronary artery calcium (CAC), a
marker of atherosclerosis, has been
shown to independently predict cardio-
vascular events as well as enhance risk
stratification in patients with diabetes
(2–5). Although recent guidelines recom-
mend consideration of CAC testing for
risk assessment in adults with diabetes
$40 years (6), we sought to evaluate
whether CAC effectively stratifies individ-
uals with diabetes across age, sex, and risk
factor (RF) burden. This question is par-
ticularly important given recent guide-
lines recommending selected use of
aspirin in patients with diabetes based
on underlying CHD risk (7).
RESEARCH DESIGN AND
METHODSdThe study cohort consisted
of 44,052 asymptomatic individuals with-
out known CHD referred for CAC screen-
ing. There were 2,384 (5.4%) individuals
with diabetes by self-report. Details for
RF collection have been described pre-
viously (8). All subjects underwent CAC
scoring at baseline and were followed for
a mean of 5.66 2.6 years (median 5 years,
range 1 to 13 years) for the primary end
point of all-cause mortality verified using
the Social Security Death Index. Annual-
ized all-cause mortality rates were esti-
mated by dividing number of deaths by
number of person-years at risk.
The population was stratified into the
following age-groups: ,50, 50–59, and
$60 years. Additionally, individuals
were stratified into high-, intermediate-,
and low-risk subgroups (based on age/sex
and presence of additional RF) per recent
guidelines detailing aspirin use in patients
with diabetes as follows: 1) high risk (10-
year cardiovascular disease [CVD] risk
.10%: ‘aspirin is reasonable’): men $50
and women$60 with 1 or more RF; 2) in-
termediate risk (10-year CVD risk 5–10%:
‘aspirin might be considered’): men $50
and women $60 without RF and men
,50 and women ,60 with RF; and 3) low
risk (10-year CVD risk,5%: ‘aspirin should
not be recommended’): men ,50 and
women ,60 without RF (7).
RESULTSdMean age of the 2,384
study subjects was 58 6 11 years; 52%
were men. A total of 500 participants
(21%) were ,50 years old, 863 (36%)
were age 50–59, and 1,021 (43%) were
at least 60 years old. A total of 535 indi-
viduals (22%) had CAC = 0, whereas 779
(33%) and 1,070 (45%) had CAC 1–100
and .100, respectively. Overall, there
were 162 deaths (6.8%). CAC was a
strong predictor of mortality in each
age-group (expressed in deaths/1,000
person-years with 95% CI): age ,50,
CAC 0: 0; CAC 1–100: 7.8 (3.7–16.3);
CAC .100: 18.2 (9.1–36.4); age 50–59,
CAC 0: 3.2 (1–10.1); CAC 1–100: 7.3
(3.9–13.5); CAC .100: 16.6 (11.1–
24.7); and age$60, CAC 0: 9.9 (4.4–22);
CAC 1–100: 19.2 (12.5–29.5); CAC.100:
33.1 (26.7–41).
Notably, all individuals $60 years
with $1 RF had a mortality rate .10
deaths/1,000 person-years.
Table 1 presents mortality rates by CAC
score according to estimated 10-year CVD
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risk category using criteria from the recent
aspirin use guidelines. It is noteworthy that
within the low and intermediate risk groups,
we observed that individuals with CAC
.100 had a mortality rate of .10 deaths/
1,000 person-years, consistent with a rec-
ommendation for aspirin therapy. Addition-
ally, absence of CAC among high-risk
individuals translated into a low risk of
6.59 deaths/1,000 person-years.
CONCLUSIONSdWe have shown
that CAC measurements may help risk
stratify patients with diabetes across age-
group, sex, and RF burden. Most individu-
alswith diabetes,60years of agehave a low
near-term risk of ,5 deaths/1,000 person-
years when CAC = 0. Additionally, we have
shown that most individuals with CAC
.100 have a mortality rate of .10
deaths/1,000 person-years. We have
also demonstrated that individuals with
diabetes $60 years have a mortality rate
of .10 deaths/1,000 person-years, re-
gardless of CAC score, when at least one
other RF is present.
Although diabetes is defined by some
guidelines as a CHD risk equivalent, the
use of aspirin for primary prevention
among individuals with diabetes remains
controversial. Given the conflicting data, a
consensus group recently provided up-
dated recommendations concluding that
patients with diabetes with a 10-year
CVD risk .10% should receive low-
dose aspirin for primary prevention (7),
further emphasizing the importance of
enhanced risk stratification among indi-
viduals with diabetes.
CAC has the potential to identify in-
dividuals who are at higher risk and thus
might benefit from aspirin (based on a 10-
year CVD risk .10%) and who may not
otherwise be identified by age and RF-
based risk estimates. Additionally, among
individuals identified as high risk by age
and RF (10-year CVD risk .10% and
thus recommended for aspirin), 16% had
CAC = 0, which translated into a mortality
rate of,10deaths/1,000person-years; this
suggests that even among individuals clas-
sified as high risk by age and RF, absence of
CAC can identify individuals with a 10-
year CVD risk,10%, whose risk of bleed-
ing from aspirin may outweigh potential
benefit.
The main limitation of our data is the
use of all-cause mortality in place of CVD
event rates. Although most deaths in
patients with diabetes are cardiovascular
in origin, many CVD events do not re-
sult in death. This would predominantly
lead to event rate underestimation. Self-
reported RF is an additional limitation.
Although the absence of continuous risk
variables may represent an additional
limitation, the use of categorical RF data
has been validated as a method of risk
stratification (9).
In conclusion, CAC has the ability to
help risk stratify individuals with diabetes
across age-group, sex, and RF burden and
may help identify individuals who may
benefit frommore aggressive therapy, such
as low-dose aspirin, for primary preven-
tion. Our study also points to individuals
with diabetes who likely will not benefit
from CAC testing, namely those$60 years
with additional RF, because their 10-year
CVD risk is .10%. Although our study is
informative, definitive recommendations
must come from clinical outcomes trials
where treatment decisions are driven by
CAC-based risk stratification.
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